WHO Sounds Alert Over Severe Lack of Obesity Injections
Under one in 10 people eligible to benefit from GLP-1 drugs including Wegovy are able to get them, caution the World Health Organization as it releases its initial guidance on the drugs.
With in excess of 1,000,000,000 people worldwide currently living with obesity, it is calling for more widespread and fairer availability to GLP-1 medication.
Per forecasts, in excess of 2,000,000,000 are projected to be living with obesity by 2030 unless action is taken.
"The new guidelines affirms that excess weight is a chronic disease that can be addressed with comprehensive and lifelong support," remarked the agency's head Tedros Adhanom Ghebreyesus.
Significant expense, insufficient output, and logistical bottlenecks are significant obstacles to widespread access to the jabs that can aid individuals in losing considerable weight, notes the body.
Weight-Loss Drug Scarcity
Even under the present best projected outlook, the production of these medications might only reach about 100 million people – under 10% of eligible patients, per the WHO.
The recommendation encourages nations and manufacturers to widen availability, via strategies like patent sharing.
The intellectual property rights on a key compound – the core ingredient of Novo Nordisk's Wegovy – is due to expire in several nations in 2026.
The Way Obesity Jabs Function
These medications mimick a body's own hormone to delay gastric emptying, curb appetite and increase the sense of being full so individuals eat less.
Individuals usually see weight reduction after several weeks of beginning the weekly injections.
Evidence suggests people may regain a significant portion within a year of halting the drug, because their usual hunger come back.
To be above a healthy weight elevates your chance for contracting medical conditions, like type 2 diabetes, cardiovascular issues, stroke, and specific malignancies.
Excess weight affects individuals in all nations and was responsible for over three and a half million fatalities worldwide in 2024, according to the health agency.
